I’m no stock-picking guru—and this is neither an endorsement to sell or to buy stock—but with all the navel gazing about the quality and durability of Winston-Salem’s tech sector
, the clearest indication may come this Thursday, when Targacept has its long-awaited IPO.
This follows on the heels of last week’s announcement regarding organ-tissue regeneration done by researchers at Wake Forest University.
Targacept is the company spun off from RJR in 2000 that does a lot of ground-breaking research on nicotine and has been working to find pharmaceutical uses for nicotine in treating diseases of the central nervous system. It cut a huge deal with AstraZeneca in December to help with the marketing and development of its products.
The stock market, as many companies find out much too late, is unforgiving and unsentimental. It cares less about the past than the future and is obsessed with expectations. And it also has a herd mentality. Money follows the leader. Targacept’s success as a publicly traded company may not be THE barometer of Winston-Salem’s tech economy, but it will be a measure worth keeping your eye on.
Your host is Ken Otterbourg, the managing editor at the Winston-Salem Journal. It's a forum to discuss the media, from